Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan for right heart failure caused by pulmonary arterial hypertension
ChiCTR2100044467Phase 4Recruiting
- Sponsor
- Vera Moulton Wall Center for Pulmonary Vascular Diseases
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tolvaptan in pulmonary arterial hypertension (PAH) and Right heart dysfunction (RHF) (2 arms), sponsored by Vera Moulton Wall Center for Pulmonary Vascular Diseases. Primary endpoints: weight and urine output. Started Sep 2020; status: recruiting.
02
Drugs
tolvaptan
03
Conditions
pulmonary arterial hypertension (PAH)Right heart dysfunction (RHF)
Beyond the preview
Go deeper on ChiCTR2100044467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044467.